Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FAB 001

X
Drug Profile

FAB 001

Alternative Names: FAB001; MUT-056399

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mutabilis
  • Developer FAB Pharma
  • Class Antibacterials; Benzamides; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action Enoyl ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in France (IV, Infusion)
  • 12 Sep 2012 Antimicrobial data from a Preclinical trial in Acinetobacter infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
  • 17 Sep 2011 Pharmacokinetics data from a preclinical trial presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top